AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Jyong Biotech Ltd. Ordinary Shares
XNAS · usd
SIC 5650 · PHARMACEUTICAL PREPARATIONS
FIGI AK-0E78D10EBD
1.77▲ 0.03 (1.72%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.74
Day's Range
1.51 – 1.82
52-Week Range
1.43 – 63.00
Volume
60.0K
Avg Volume
48.8K
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2025-06-17
Share count as of December 31, 2025

Jyong Biotech Ltd. Ordinary Shares (MENS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Jyong Biotech Ltd. Ordinary Shares (MENS)
What is Jyong Biotech Ltd. Ordinary Shares's Market Cap?
Jyong Biotech Ltd. Ordinary Shares's Market Cap is $134.6M, based on as-reported figures from SEC (XBRL) filings.
What is Jyong Biotech Ltd. Ordinary Shares's Enterprise Value?
Jyong Biotech Ltd. Ordinary Shares's Enterprise Value is $135.5M, based on as-reported figures from SEC (XBRL) filings.
What is Jyong Biotech Ltd. Ordinary Shares's EV / EBITDA?
Jyong Biotech Ltd. Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Jyong Biotech Ltd. Ordinary Shares's Net Income (TTM)?
Jyong Biotech Ltd. Ordinary Shares's Net Income (TTM) is -$4.7M, based on as-reported figures from SEC (XBRL) filings.
What is Jyong Biotech Ltd. Ordinary Shares's EBITDA?
Jyong Biotech Ltd. Ordinary Shares's EBITDA is -$2.5M, based on as-reported figures from SEC (XBRL) filings.
What is Jyong Biotech Ltd. Ordinary Shares's Diluted EPS (TTM)?
Jyong Biotech Ltd. Ordinary Shares's Diluted EPS (TTM) is -0.06, based on as-reported figures from SEC (XBRL) filings.
What is Jyong Biotech Ltd. Ordinary Shares's Net Debt?
Jyong Biotech Ltd. Ordinary Shares's Net Debt is $946.0K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MENSAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023
Operating expenses
Research and development
Selling and marketing
General and administrative
Total operating expenses
Loss from operations
Other incomes (expenses):
Interest income
Interest expenses
Other (losses) gains, net
Total other expenses, net
Loss before income tax
Net loss
Basic (in Dollars per share)
Diluted (in Dollars per share)